{
    "clinical_study": {
        "@rank": "13116", 
        "arm_group": [
            {
                "arm_group_label": "DCAG plus DLI", 
                "arm_group_type": "Experimental", 
                "description": "Patient will be treated with decitabine and modified CAG regimen followed by HLA haploidentical peripheral mononuclear blood cells infusion"
            }, 
            {
                "arm_group_label": "DCAG", 
                "arm_group_type": "Active Comparator", 
                "description": "Patients will be treated with decitabine and modified CAG regimen"
            }
        ], 
        "brief_summary": {
            "textblock": "Demethylating agent decitabine enhances the immunogenicity of leukemia cells by inducing the\n      expression of cancer testis antigens (CTAs),MHC class I and II molecules,costimulatory\n      molecules and adhesion molecules. The leukemias cells treated by decitabine will become more\n      sensitive to the following adoptive T cell therapy."
        }, 
        "brief_title": "Decitabine Combining Modified CAG Followed by HLA Haploidentical Peripheral Blood Mononuclear Cells Infusion for Elderly Patients With Intermediate-high Risk Myelodysplastic Syndrome(MDS) or Acute Myeloid Leukemia(AML\uff09", 
        "completion_date": {
            "#text": "November 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "MDS", 
            "AML"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Leukemia", 
                "Leukemia, Myeloid, Acute", 
                "Leukemia, Myeloid", 
                "Myelodysplastic Syndromes", 
                "Preleukemia"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "PATIENT Inclusion Criteria:\n\n          -  Must have a diagnosis of MDS-RAEB or AML based on 2008 World Health Organization\n             (WHO) classification of myeloid malignancies\n\n          -  Must have life expectancy >= 3 months\n\n          -  Must have the ability to observe the efficacy and events\n\n          -  Must have no accompany therapy(including steroid)\n\n          -  Patient must have ability to understand and willingness to provide written informed\n             consent prior to participation in the study and any related procedures being\n             performed\n\n          -  Must have an Eastern Cooperative Oncology Group (ECOG) performance status =< 3\n\n          -  Must have haploidentical donor\n\n        DONOR Inclusion Criteria:\n\n          -  Must have signed the standard informed consent form; if sufficient cryopreserved\n             cells remain from a previous donation, no additional donation or consent is required\n\n          -  Both men and women and members of all races and ethnic groups are eligible for this\n             trial\n\n        PATIENT Exclusion Criteria:\n\n          -  Must not have an advanced malignant hepatic tumor\n\n          -  Must not receive any other forms of chemotherapy after cell infusion during the\n             treatment protocol\n\n          -  Must not be receiving any other investigational agents within 14 days of first dose\n             of study drug\n\n          -  Must not have uncontrolled intercurrent illness including ongoing or active\n             infection, symptomatic congestive heart failure, unstable angina pectoris, or\n             psychiatric illness/social situations that would limit compliance with study\n             requirements\n\n          -  Must not be pregnant or breastfeeding; pregnant women are excluded from this study\n             because decitabine is a Category D agent with the potential for teratogenic or\n             abortifacient effects; because there is an unknown but potential risk for adverse\n             events in nursing infants secondary to treatment of the mother with decitabine,\n             breastfeeding should be discontinued if the mother is treated with decitabine; these\n             potential risks may also apply to other agents used in this study\n\n          -  Must not have a history of allergic reactions attributed to compounds of similar\n             chemical or biologic composition to decitabine or other agents used in the study\n\n          -  Must not have a known or suspected hypersensitivity to decitabine\n\n          -  Must not be human immunodeficiency virus (HIV)-positive and on combination\n             antiretroviral therapy; these patients are ineligible because of the potential for\n             pharmacokinetic interactions with decitabine; in addition, these patients are at\n             increased risk of lethal infections when treated with marrow-suppressive therapy;\n             appropriate studies will be undertaken in patients receiving combination\n             antiretroviral therapy when indicated\n\n        DONOR Exclusion Criteria:\n\n          -  Must not have any underlying conditions which would contra-indicate apheresis\n\n          -  Must not be pregnant"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "60 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 19, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01690507", 
            "org_study_id": "CN301-XYK-001"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "DCAG plus DLI", 
                    "DCAG"
                ], 
                "description": "20 mg/m\u00b2/day for 5 days", 
                "intervention_name": "Decitabine", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "DCAG plus DLI", 
                    "DCAG"
                ], 
                "intervention_name": "Cytarabine", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "DCAG plus DLI", 
                    "DCAG"
                ], 
                "intervention_name": "aclacinomycin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "DCAG plus DLI", 
                    "DCAG"
                ], 
                "intervention_name": "Granulocyte colony-stimulating factor", 
                "intervention_type": "Drug", 
                "other_name": "G-CSF"
            }, 
            {
                "arm_group_label": "DCAG plus DLI", 
                "intervention_name": "HLA haploidentical mononuclear cells infusion", 
                "intervention_type": "Other", 
                "other_name": "DLI"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Cytarabine", 
                "Decitabine", 
                "Aclacinomycins", 
                "Lenograstim"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "demethylating agent", 
            "immunogenicity"
        ], 
        "lastchanged_date": "January 30, 2013", 
        "location": [
            {
                "contact": {
                    "email": "wanglixin1991@sohu.com", 
                    "last_name": "Li-Xin Wang, M.D Ph.D", 
                    "phone": "86-010-66958509"
                }, 
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China", 
                        "state": "Beijing", 
                        "zip": "100048"
                    }, 
                    "name": "Navy General Hospital"
                }, 
                "investigator": {
                    "last_name": "Li-Xin Wang, M.D. Ph.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "chunhuiliyu@yahoo.com", 
                    "last_name": "Li Yu, M.D. Ph.D.", 
                    "phone": "86-010-55499003"
                }, 
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China", 
                        "zip": "100853"
                    }, 
                    "name": "Chinese PLA General Hospital"
                }, 
                "investigator": {
                    "last_name": "Li Yu, M.D. Ph.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "Phase 1/2 Study of Decitabine Combined With Modified CAG Followed by HLA Haploidentical T Cell Infusion in Treating Elderly Patients With Intermediate-high Risk Myelodysplastic Syndrome(MDS) or Acute Myeloid Leukemia(AML\uff09", 
        "overall_contact": {
            "email": "chunhuiliyu@yahoo.com", 
            "last_name": "Li Yu, M.D. Ph.D.", 
            "phone": "86-010-55499003"
        }, 
        "overall_contact_backup": {
            "email": "wanglixin1991@sohu.com", 
            "last_name": "Li-Xin Wang, M.D. Ph.D.", 
            "phone": "86-010-66958509"
        }, 
        "overall_official": {
            "affiliation": "Chinese PLA General Hospital", 
            "last_name": "Li Yu, M.D. Ph.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Ethics Committee", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "February 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "overall survival", 
                "safety_issue": "Yes", 
                "time_frame": "3 years"
            }, 
            {
                "measure": "event free survival", 
                "safety_issue": "Yes", 
                "time_frame": "3 years"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01690507"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Chinese PLA General Hospital", 
            "investigator_full_name": "Li Yu", 
            "investigator_title": "Director of Department of Hematology and BMT Center", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "complete remission rate", 
                "safety_issue": "Yes", 
                "time_frame": "4 months"
            }, 
            {
                "measure": "overall response rate", 
                "safety_issue": "Yes", 
                "time_frame": "4 months"
            }
        ], 
        "source": "Chinese PLA General Hospital", 
        "sponsors": {
            "collaborator": {
                "agency": "Navy General Hospital, Beijing", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Chinese PLA General Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2013"
    }
}